TheStreet

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

PRESS RELEASES

By GlobeNewswire
Mar 25, 2021 4:05 PM EDT

PRESS RELEASES

By GlobeNewswire
Mar 16, 2021 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Mar 15, 2021 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Mar 10, 2021 4:05 PM EST

PRESS RELEASES

By GlobeNewswire
Mar 4, 2021 4:05 PM EST

PRESS RELEASES

By GlobeNewswire
Mar 2, 2021 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Feb 16, 2021 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Jan 19, 2021 4:05 PM EST

PRESS RELEASES

By PR Newswire
Jan 7, 2021 9:46 AM EST

PRESS RELEASES

By GlobeNewswire
Jan 6, 2021 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Jan 5, 2021 4:05 PM EST

PRESS RELEASES

By GlobeNewswire
Dec 30, 2020 10:25 PM EST

PRESS RELEASES

By GlobeNewswire
Dec 17, 2020 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Dec 1, 2020 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Nov 16, 2020 4:05 PM EST

PRESS RELEASES

By GlobeNewswire
Nov 12, 2020 8:00 AM EST

PRESS RELEASES

By GlobeNewswire
Oct 28, 2020 4:30 PM EDT

PRESS RELEASES

By GlobeNewswire
Oct 27, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Oct 19, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Oct 5, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Sep 29, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Sep 16, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Sep 10, 2020 8:00 AM EDT

PRESS RELEASES

By GlobeNewswire
Sep 1, 2020 4:15 PM EDT

Trade with Jim Cramer 14 Days Free

Histogen Appoints Rochelle Fuhrmann To Board Of Directors

Histogen And Amerimmune Announce First Patient Dosed In Phase 1 Study Of Emricasan In Symptomatic COVID-19 Patients

Histogen Announces Removal Of Clinical Hold By FDA For HST-003 IND To Initiate A Phase 1/2 Trial For Knee Cartilage Regeneration

Histogen Strengthens Board Of Directors With Appointment Of Industry Leader Susan Windham-Bannister, Ph.D.

Histogen To Report Fourth Quarter And Year-End 2020 Financial Results And Provide Business Update

Histogen To Present At The H.C. Wainwright Global Life Sciences Virtual Conference

Histogen Announces Week 26 HST-001 Study Results For The Treatment Of Androgenic Alopecia In Men

Histogen Reports FDA Clinical Hold For Planned Phase 1/2 Trial Of HST-003 For Knee Cartilage Regeneration

DLA Piper Advises Histogen In Its US$14 Million Upsized Public Offering

Histogen To Present At The H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Histogen Announces Closing Of $14.0 Million Upsized Public Offering

Histogen Announces Pricing Of $14.0 Million Upsized Public Offering

Histogen Announces Filing An Investigational New Drug Application For HST-003

Histogen Announces Preliminary Week 18 HST-001 Study Results For The Treatment Of Androgenic Alopecia In Men

Histogen Announces Closing Of $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Histogen To Report Third Quarter 2020 Earnings On November 12, 2020

Histogen And Amerimmune Enter Into A Collaborative Development And Commercialization Agreement For Emricasan In The Treatment Of COVID-19

Histogen Appoints Moya Daniels As Executive Vice President And Head Of Regulatory, Quality And Clinical Operations

Histogen Announces Completion Of Final Dosing Timepoint Milestone In Its 1b/2a Trial For Androgenic Alopecia In Men

Histogen Announces Update For Its HST-002 Dermal Filler Program

Histogen Announces $2M Grant Award From The Department Of Defense For Clinical Advancement Of HST-003 For Cartilage Regeneration In The Knee

Histogen Announces Completion Of Dosing Milestone In Its 1b/2a Trial For Androgenic Alopecia In Men

Histogen To Present At The HC Wainwright 22nd Annual Global Investment Conference